LifeMD Announces Exclusive Collaboration to Launch Direct-to-Patient Self-Pay Program for XYOSTED® (testosterone enanthate) Injection

Stock Information for LifeMD Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About LifeMD Inc.

LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
LifeMD Appoints Umesh Sripad as Chief Technology Officer
LifeMD to Participate in Upcoming Investor Conferences
LifeMD Reports First Quarter 2026 Results
LifeMD to Report First Quarter 2026 Financial Results on May 6
LifeMD® Now Offering Eli Lilly and Company's Foundayo(TM) (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.